Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Negative 61.3%

Neg 61.3% Neu 0% Pos 0%

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.